Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06331585 | Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy | withdrawn | Phase 2 | 0 | Hetian District People's HospitalOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05705466 | Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Kartos Therapeutics, Inc.INDUSTRY | 0 | Mar 22, 2024 | clinicaltrials |
| NCT04102436 | Non-Viral TCR Gene Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06052423 | ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Mar 4, 2024 | clinicaltrials |
| NCT03190239 | Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients(XQonc-007) | withdrawn | Phase 2 | 0 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT02531854 | A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy | withdrawn | Phase 2 | 0 | Advaxis, Inc.INDUSTRY | 0 | Dec 19, 2023 | clinicaltrials |
| NCT05948462 | Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib(NSCLC) | withdrawn | Phase 2 | 0 | SCRI Development Innovations, LLCOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT05737849 | A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)(ELEGANT) | withdrawn | — | 0 | TakedaINDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05161533 | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05180422 | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | withdrawn | Phase 1 / Phase 2 | 0 | Criterium, Inc.INDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05863819 | A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)(MEANING-20) | withdrawn | — | 0 | TakedaINDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT04989283 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05045404 | Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT05287971 | Standard of Care Lifestyle Support for Stage III NSCLC Patients(PERCUSSION) | withdrawn | — | 0 | Maastricht Radiation OncologyOTHER | 0 | Sep 6, 2023 | clinicaltrials |
| NCT05230888 | Comprehensive Geriatric Assessment in Elderly Non-Small Cell Lung Cancer Patients | withdrawn | — | 0 | University of HullOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05935774 | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05791097 | Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.(AdvanTIG-306) | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 24, 2023 | clinicaltrials |
| NCT05171062 | Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05400577 | Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT04466917 | A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 3 | 0 | AmgenINDUSTRY | 0 | Jul 3, 2023 | clinicaltrials |
| NCT05603299 | Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test | withdrawn | N/A | 0 | Qure Healthcare, LLCINDUSTRY | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Ellipses PharmaINDUSTRY | 3 | Jun 12, 2023 | clinicaltrials |
| NCT04699968 | A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jun 7, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT04625699 | Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment | withdrawn | Phase 2 | 0 | Catherine ShuOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT02607423 | Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT01971489 | Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT03632369 | Hyperpolarized Noble Gas MRI Detection of Radiation-Induced Lung Injury | withdrawn | — | 0 | Thunder Bay Regional Health Research InstituteOTHER | 0 | Apr 25, 2023 | clinicaltrials |
| NCT05212922 | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC(YH001) | withdrawn | Phase 2 | 0 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT05693090 | Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Kura Oncology, Inc.INDUSTRY | 1 | Mar 6, 2023 | clinicaltrials |
| NCT04650490 | SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer(STICk-IM-NSCLC) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | withdrawn | N/A | 0 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 0 | Dec 22, 2022 | clinicaltrials |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | withdrawn | Phase 1 | 0 | Instil BioINDUSTRY | 0 | Dec 20, 2022 | clinicaltrials |
| NCT05481775 | Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT05116618 | Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged | withdrawn | — | 0 | University of Colorado, DenverOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05022394 | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Elpiscience Biopharma, Ltd.INDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT04754815 | Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC(HFHS 21-01) | withdrawn | Phase 2 | 0 | Shirish GadgeelOTHER | 0 | Mar 29, 2022 | clinicaltrials |
| NCT03770299 | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease(CheckMate 9TN) | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Mar 24, 2022 | clinicaltrials |
| NCT02662634 | A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | GU Research Network, LLCOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04061590 | Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04470674 | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients | withdrawn | Phase 2 | 0 | Shirish M GadgeelOTHER | 1 | Mar 3, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 25, 2024source: clinicaltrials